



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		O I P E MAY 04 2001 P A T E N T & T R ADE M A R K O F F I C E	Docket Number (Optional) <b>D-0021.3A</b>	Application Number <b>09/772,719</b>
*EXAMINER <i>[Signature]</i>	OTHER DOCUMENTS Author, Title, Date, Pertinent Pages, Etc.)	Applicant(s) <b>Zavada et al.</b>		
INITIAL	Filing Date <b>January 30, 2001</b>			
<p>Divgi et al., "Scintigraphy of Renal Cell Carcinoma with I-131 Labelled Monoclonal Antibody (MAB) G250," <i>European Journal of Nuclear Medicine</i>, 19(8): 578 (Abstract 121-3) (August 23, 1992)</p> <p>Divgi et al., "Radioimmunotherapy (RIT) with I-131 Monoclonal Antibody (Mab) G250 in Metastatic Renal Cancer," <i>Proceedings of the 41st Annual Meeting</i>, 35(5): 101P (Abstract #401) (May 1994)</p> <p>Divgi et al., "Radioimmunotherapy with I-131-G250 in Metastatic Renal Cell Cancer (RCC)," <i>J. Nucl. Med.</i>, 36 (5 Suppl.): 913P (Abstract 956; May 1995)</p> <p>Frohman et al., "Rapid production of full-length cDNAs from rare transcripts: Amplification using a single gene-specific oligonucleotide primer," <i>PNAS (USA)</i>, 85: 8998-9002 (December 1988)</p> <p>Frosch et al., "Cloning and characterisation of an immunodominant major surface antigen of <i>Echinococcus multilocularis</i>," <i>Molecular and Biochemical Parasitology</i>, 48: 121-130 (1991)</p> <p>Kranenborg et al., "Development and Characterization of Anti-Renal Cell Carcinoma X Antichelate Bispecific Monoclonal Antibodies for Two-Phase Targeting of Renal Cell Carcinoma," <i>Cancer Res.</i>, 55 (23 Suppl.): 5864s-5867s (1995)</p> <p>Kurth et al., "Characterization of Human Renal Cell Carcinoma Tumor Lines by Means of Monoclonal Antibodies," <i>Prostate</i>, 6(4): 451 (Abstract) (1985)</p> <p>Liao et al., "Identification of the MN Antigen as a Diagnostic Biomarker of Cervical Intraepithelial Squamous and Glandular Neoplasia and Cervical Carcinomas," <i>American Journal of Pathology</i>, 145(3): 598-609 (September 1994)</p> <p>Luner et al., "Monoclonal Antibodies to Kidney and Tumor-associated Surface Antigens of Human Renal Cell Carcinoma," <i>Cancer Res.</i>, 46(11): 5816-5820 (1986)</p> <p>Moon et al., "A Highly Restricted Antigen for Renal Cell Carcinoma Defined by a Monoclonal Antibody," <i>Hybridoma</i>, 4(2): 163-172 (1985)</p> <p>Oosterwijk and Debruyne, "Radiolabeled monoclonal antibody G250 in renal-cell carcinoma," <i>World Journal of Urology</i>, 13: 186-190 (1995)</p> <p>Oosterwijk et al., "The Expression of Renal Antigens in Renal Cell Carcinoma," <i>World Journal of Urology</i>, 2(2): 156-158 (1984)</p>				
EXAMINER <i>[Signature]</i>	DATE CONSIDERED	12/20/02		

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

## INFORMATION DISCLOSURE

(Use several sheets if necessary)

CITATION

MAY 04 2001



Docket Number (Optional)

D-0021.3A

Application Number

09/772,719

Applicant(s)

Zavada et al.

Filing Date

January 30, 2001

Group Art Unit

EXAMINER  
INITIALS

## OTHER DOCUMENTS (Indicating Author, Title, Date, Pertinent Pages, Etc.)

Oosterwijk et al., "Monoclonal Antibodies that Discriminate Between Renal Cell Carcinomas (RCC) and Other Malignancies," Prostate, 6(4): 451-452 (Abstract) (1985)

Oosterwijk et al., "Immunohistochemical Analysis of Monoclonal Antibodies to Renal Antigens -- Application in the Diagnosis of Renal Cell Carcinoma," American Journal of Pathology, 123(2): 301-309 (May 1986)

Oosterwijk et al., "Monoclonal Antibody G250 Recognizes a Determinant Present in Renal-Cell Carcinoma and Absent from Normal Kidney," Int. J. Cancer, 38: 489-494 (1986)

Oosterwijk et al., "Relationship between DNA Ploidy, Antigen Expression and Survival in Renal Cell Carcinoma," Int. J. Cancer, 42: 703-708 (1988)

Oosterwijk et al., "Expression of Intermediate-sized Filaments in Developing and Adult Human Kidney and Renal Cell Carcinoma," The Journal of Histochemistry and Cytochemistry, 38(3): 385-392 (1990)

Oosterwijk et al., "Antibody Localization in Human Renal Cell Carcinoma: A Phase I Study of Monoclonal Antibody G250," Journal of Clinical Oncology, 11(4): 738-750 (April 1993)

Oosterwijk et al., "The Use of Monoclonal Antibody G250 in the Therapy of Renal-Cell Carcinoma," Seminars in Oncology, 22(1): 34-41 (February 1995)

Oosterwijk et al., "Molecular characterization of the Renal Cell Carcinoma-associated antigen G250," Proceedings of the American Association for Cancer Research, 37: 461 (Abstract #3147) (March 1996)

Opavsky et al., "Regulation of MN Expression," Cell Biology International, 18(5): Abstract No. Mo-58 (1994)

Pastorek et al., "The Structure and Expression of MN Gene, Coding for a Tumor-Associated Protein p54/58N," J. Cancer Res. Clin. Oncol., 119 (Suppl. 1) 10/113 (1993)

Pastorek et al., "Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment," Oncogene, 9: 2877-2888 (1994)

Pastorek et al., "MN - A Novel Type of Oncoprotein," Cell Biology International, 18(5): Abstract No. Mo-57 (1994)

EXAMINER

DATE CONSIDERED

12/20/02

\* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

MAY 04 2001

MAILED

RECEIVED

U.S. PATENT AND TRADEMARK OFFICE

Docket Number (Optional)

D-00213A-2

Application Number

09/772,719

Applicant(s)

Zavada et al.

Filing Date

January 30, 2001

Group Art Unit

EXAMINER  
INITIAL

## OTHER DOCUMENTS (Indicating Author, Title, Date, Pertinent Pages, Etc.)

- GW*
- Pastorekova et al., "A Novel Quasi-viral Agent, MaTU, Is a Two-Component System," *Virology*, 187: 620-626 (1992)
- Pastorekova et al., "Transformation of Mammalian Cells by MN Oncogene," *Cell Biology International*, 18(5): Abstract No Mo-56 (1994)
- Stanbridge et al., "Specific Chromosome Loss Associated with the Expression of Tumorigenicity in Human Cell Hybrids", *Somatic Cell Genetics*, 7(6): 699-712 (1981)
- Stanbridge et al., "Human Cell Hybrids: Analysis of Transformation and tumorigenicity", *Science*, 215: 252-259 (January 15, 1982)
- Surfat et al., "Renal Cell Human-Mouse Chimeric Antibody G250 Mediates Antibody Dependent Cellular Cytotoxicity (ADCC)," *Biological Abstracts*, 47(9): 161224 (Abstract 3922) (1995)
- Tweedie and Edwards, "Mouse Carbonic Anhydrase III: Nucleotide Sequence and Expression Studies," *Biochemical Genetics*, 27(1/2): 17-30 (1989)
- Uemura et al., "Internal Image Anti-Idiotype Antibodies Related to Renal-Cell Carcinoma-Associated Antigen G250," *Int. J. Cancer*, 56: 609-614 (1994)
- Uemura et al., "Vaccination with Anti-Idiotype Antibodies Mimicking a Renal Cell Carcinoma-Associated Antigen Induces Tumor Immunity," *Int. J. Cancer*, 58: 555-561 (1994)
- Uemura et al., "Immunization with Anti-Idiotype Monoclonal Antibodies Bearing the Internal Image of the Renal-Cell Carcinoma-Associated Antigen G250 Induces Specific Cellular Immune Responses," *Int. J. Cancer*, 59: 802-807 (1994)
- Uemura et al., "Anti-tumor effects of vaccination with internal image anti-idiotype monoclonal antibodies," *Biotherapy (Japan)*, 9(3): 294-295 (1995) (English Language Summary)
- Uemura et al., "Expression of Tumor-Associated Antigen MN/G250 in Urologic Carcinoma: Potential Therapeutic Target," *Journal Urology*, 157 (4-Supp.): 377 (April 16, 1997)
- Van Dijk et al., "Induction of Tumor-Cell Lysis by Bi-Specific Monoclonal Antibodies Recognizing Renal-Cell Carcinoma and CD3 Antigen," *Int. J. Cancer*, 43: 344-349 (1989)

EXAMINER

*GW*

DATE CONSIDERED

12/20/02

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE CITATION**  
 (Use several sheets if necessary)

O I P E  
 SC 54  
 MAY 8 4 2001  
 PATENT TRADEMARK OFFICE

Docket Number (Optional)

D-0021.3A-2

Application Number

09/772,719

Applicant(s)

Zavada et al.

Filing Date

January 30, 2001

Group Art Unit

\*EXAMINER  
 INITIAL

OTHER DOCUMENTS (In BRAILLE Author, Title, Date, Pertinent Pages, Etc.)

Van Dijk et al., "Therapeutic Effects of Monoclonal Antibody G250, Interferons and Tumor Necrosis Factor, In Mice with Renal-Cell Carcinoma Xenografts," *Int. J. Cancer*, 56: 262-268 (1994)

Vessella et al., "Monoclonal antibodies to human renal cell carcinoma: recognition of shared and restricted tissue antigens," *Cancer Res.*, 45(12, Pt. 1): 6131-6139 (1985)

Young and Davis, "Efficient Isolation of Genes by Using Antibody Probes," *PNAS (USA)* 80: 1194-1198 (March 1983)

Zavada, "The Pseudotypic Paradox," *J. gen. Virol.*, 63: 15-24 (1982)

Zavada and Zavadova, "A Transmissible Antigen Detected in Two Cell Lines Derived from Human Tumours," *J. gen. Virol.* 24: 327-337 (1974)

Zavada and Zavadova, "An unusual transmissible agent - MaTu," *Arch. Virol.*, 118: 189-197 (1991)

Zavada et al., "VSV Pseudotype Produced in Cell Line derived from Human Mammary Carcinoma," *Nature New Biology*, 240: 124-125 (November 22, 1972)

Zavada et al., "Tumorigenicity-Related Expression of MaTu Proteins in HeLa x Fibroblast Hybrids," Abstract presented at the XIX Meeting of the European Tumor Virus Group (May 1-4, 1991)

Zavada et al., "Expression of MaTu-MN Protein in Human Tumor Cultures and in Clinical Specimens," *Int. J. Cancer*, 54: 268-274 (1993)

Zavada et al., "A Presumed New Oncoprotein - MN - Used as Experimental Antitumor Vaccine," *J. Cancer Res. Clin. Oncol.* 119, (Suppl. 1) 2/24 (1993)

EXAMINER

*EW*

DATE CONSIDERED

*12/20/02*

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.